Companies ›Healthcare ›COIL.L

COIL.L — London Stock Exchange Biotechnology & Medical Research

Coiled Therapeutics PLC

$10,50

Open in Charts → Attach watcher ⌖

— —

GBp

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

4,5B GBp

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Coiled Therapeutics PLC is a biotechnology company focused on the development of novel therapeutics for the treatment of respiratory diseases, primarily through its proprietary inhaled drug delivery platform.

Business. Coiled Therapeutics PLC (COIL.L) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

PNC Investments LLC

largest disclosed fund holder

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning COIL.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to COIL.L. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Coiled Therapeutics PLC (COIL.L) is a biotechnology and medical research company operating within the healthcare diagnostics sector. The firm is headquartered in the United Kingdom and is primarily listed on the London Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

Coiled Therapeutics has a market capitalization of £481.2 million, with a market price of £11.3 per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 425.86 million shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company has not disclosed profitability metrics such as net income or EBITDA, and therefore, no direct comparison to industry_config preferred metrics can be made. The lack of financial data limits the ability to assess returns or margins relative to the biotechnology industry median.

Coiled Therapeutics operates as a single-segment company, with all operations and revenue exposure concentrated in the United Kingdom. There is no disclosed geographic diversification, and the company does not report revenue by business segment.

The company has not provided a formal growth outlook for the current or next fiscal year. With no revenue history or forward-looking guidance available, it is not possible to assess the trajectory of revenue growth or operational expansion.

The primary risk factor is the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is currently not at risk of dilution, as there is no difference between basic and diluted shares outstanding.

No recent events, such as filings or transcripts, have been disclosed in the available data. The company has not issued press releases or filed 10-K/annual reports that would provide insight into recent strategic or operational developments.

Key takeaways

Coiled Therapeutics is a UK-based biotechnology company focused on respiratory disease therapeutics.
The company has no dilution risk, with basic and diluted shares outstanding being equal.
Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
The company operates as a single-segment entity with all operations in the UK.
No profitability metrics or growth outlooks are available, limiting the ability to assess performance or future potential.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$10,50

Market cap

$4.81B

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Coiled Therapeutics PLC Market data — financials · 2026-05-27

Ownership & reference

Top holders

PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Sotirios StergiopoulosExecutive Chairman of the Board

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

COIL.LCanonical

London Stock Exchange · GBp

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread